207 related articles for article (PubMed ID: 25216515)
1. RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.
Huang Y; Zhao M; Xu H; Wang K; Fu Z; Jiang Y; Yao Z
Oncotarget; 2014 Aug; 5(16):6734-45. PubMed ID: 25216515
[TBL] [Abstract][Full Text] [Related]
2. RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
Hui K; Gao Y; Huang J; Xu S; Wang B; Zeng J; Fan J; Wang X; Yue Y; Wu S; Hsieh JT; He D; Wu K
Cell Death Dis; 2017 Feb; 8(2):e2600. PubMed ID: 28182001
[TBL] [Abstract][Full Text] [Related]
3. Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway.
Fan D; Yu S; Yang Y; Qu S
Biol Pharm Bull; 2021; 44(7):992-998. PubMed ID: 34193694
[TBL] [Abstract][Full Text] [Related]
4. RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition.
Li N; Li S
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):358-62. PubMed ID: 25446096
[TBL] [Abstract][Full Text] [Related]
5. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
[TBL] [Abstract][Full Text] [Related]
6. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.
McLaughlin SK; Olsen SN; Dake B; De Raedt T; Lim E; Bronson RT; Beroukhim R; Polyak K; Brown M; Kuperwasser C; Cichowski K
Cancer Cell; 2013 Sep; 24(3):365-78. PubMed ID: 24029233
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
8. RASAL2 activates RAC1 to promote triple-negative breast cancer progression.
Feng M; Bao Y; Li Z; Li J; Gong M; Lam S; Wang J; Marzese DM; Donovan N; Tan EY; Hoon DS; Yu Q
J Clin Invest; 2014 Dec; 124(12):5291-304. PubMed ID: 25384218
[TBL] [Abstract][Full Text] [Related]
9. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
10. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
Liu L; Wu N; Wang Y; Zhang X; Xia B; Tang J; Cai J; Zhao Z; Liao Q; Wang J
J Exp Clin Cancer Res; 2019 Feb; 38(1):106. PubMed ID: 30819230
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of RASAL2 promotes the proliferation, epithelial-mesenchymal transition and metastasis of colorectal cancer cells.
Jia Z; Liu W; Gong L; Xiao Z
Oncol Lett; 2017 Mar; 13(3):1379-1385. PubMed ID: 28454265
[TBL] [Abstract][Full Text] [Related]
12. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
13. CXCR7 signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas.
Yu H; Zhang L; Liu P
Tumour Biol; 2015 Mar; 36(3):1679-83. PubMed ID: 25359618
[TBL] [Abstract][Full Text] [Related]
14. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.
Fan X; Wang Y; Fan J; Chen R
J Cell Biochem; 2019 Jun; 120(6):10643-10651. PubMed ID: 30672020
[TBL] [Abstract][Full Text] [Related]
15. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
16. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.
Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y
Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599
[TBL] [Abstract][Full Text] [Related]
17. Targeting UDP-glucose dehydrogenase inhibits ovarian cancer growth and metastasis.
Lin LH; Chou HC; Chang SJ; Liao EC; Tsai YT; Wei YS; Chen HY; Lin MW; Wang YS; Chien YA; Yu XR; Chan HL
J Cell Mol Med; 2020 Oct; 24(20):11883-11902. PubMed ID: 32893977
[TBL] [Abstract][Full Text] [Related]
18. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.
Malgundkar SH; Burney I; Al Moundhri M; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
BMC Cancer; 2020 May; 20(1):374. PubMed ID: 32366234
[TBL] [Abstract][Full Text] [Related]
19. High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis.
Hou M; Cheng Z; Shen H; He S; Li Y; Pan Y; Feng C; Chen X; Zhang Y; Lin M; Wang L; Ke Z
Oncotarget; 2015 Nov; 6(34):35813-29. PubMed ID: 26452130
[TBL] [Abstract][Full Text] [Related]
20. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
